Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A 19-year-old used a 0.01% topical finasteride formula, which unexpectedly lowered DHT levels significantly. They are considering reducing the dose further and exploring alternatives like ketoconazole shampoo, KX826, and CB to manage hair loss while minimizing systemic absorption.

Switching from finasteride to dutasteride may cause increased hair shedding, which is not well-documented in clinical trials. Some users report success with dutasteride, but experiences vary, and expectations may influence perceptions of effectiveness.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

The conversation is about hair loss and the effectiveness of treatments like finasteride, with one user expressing satisfaction after seeing hair regrowth on CCTV. Other users share their experiences with hair visibility and discuss the effectiveness of finasteride compared to dutasteride.

The conversation discusses various hair loss treatments, including minoxidil, finasteride, dutasteride, pyrilutamide, alfatrodial, and nizoral, with a focus on the potential of new treatments like gt20029 and breezula. There is optimism about novel treatments that don't have systemic effects, although skepticism remains about the effectiveness of some new drugs.

The user reported high testosterone and estradiol levels within range, but unexpectedly high DHT levels after using finasteride and dutasteride for hair loss. Another person suggested the dutasteride might be fake or a bad batch and recommended using the branded Avodart.

The user is addressing hair loss with finasteride, dutasteride, oral and topical minoxidil, dermarolling, and shampoos. They are considering adding essential oils to improve circulation.

The user is experiencing hair loss despite using finasteride three times a week due to side effects and is considering alternatives like topical finasteride, estrogen blockers, or dutasteride. They are also interested in potential treatments like GT20029 and pyrilutamide.

The user has been using finasteride for over two years with mixed results and is considering starting dutasteride and oral minoxidil, though both are hard to obtain. They are also contemplating a hair transplant in the future due to diffuse thinning.

The conversation discusses a user's positive experience with hair loss treatments, including Duoxidil, oral Dutasteride, oral Minoxidil, and biotin, noting no side effects and effective results. The user plans to start a new cycle of Dutasteride and PRP sessions.

The conversation discusses transitioning from daily oral Dutasteride to a long-term maintenance protocol for hair loss, considering options like oral Finasteride with topical Dutasteride, pulsed oral Dutasteride, and oral Finasteride with topical Finasteride. The consensus suggests maintaining a baseline with daily Finasteride and using Dutasteride twice a week to minimize shedding while reducing systemic exposure.

The discussion revolves around the need for future oral DHT blockers for hair loss treatment that don't have the side effects of current options like Finasteride and Dutasteride. One user suggests that the future of hair loss treatment will likely be topical anti-androgens, as they can target hair follicles without affecting the entire system.

GT20029 and KX826 are promising hair loss treatments, with GT20029 increasing hair count and KX826 showing significant results. KX826 may be a good alternative for those who can't use finasteride or dutasteride, though results vary.

Hair cloning technology is advancing, with clinical trials for improved methods expected by 2028 and 2029, potentially offering a solution for hair loss if donor follicles remain. Organtech's expansion into other biotech areas may secure funding, but the effectiveness of cloning depends on the availability of androgen-resistant donor follicles.

The conversation discusses switching from finasteride to dutasteride for hair loss treatment, with users sharing experiences and strategies for transitioning, such as alternating days or gradual introduction to avoid shedding. Some users report worsening hair conditions and side effects like low libido after switching.

The conversation discusses alternatives to finasteride for hair loss, including topical treatments like minoxidil, RU58841, CB-03-01, and dutasteride. Users also mention other options like alfatradiol, topical caffeine, and mesotherapy, while expressing concerns about side effects and the effectiveness of these treatments.

The conversation is about hair regrowth progress using oral dutasteride (DUT) and minoxidil (MIN) over three months, with significant improvement noted. Users discuss potential future results and share personal experiences with similar treatments.

The user switched from finasteride to dutasteride 0.5 mg daily due to worsening hair loss and is seeking opinions on any noticeable regrowth or improvement. Some users suggest there might be more thick hairs, while others find it hard to compare due to different photo angles.

Finasteride and Dutasteride will remain accessible in the EU despite objections from France and Belgium. Users discuss the ease of obtaining these medications in different countries and express relief and support for the EU's decision.

Microneedling before applying topical finasteride or dutasteride may enhance their effectiveness by increasing local absorption in the scalp, despite concerns about systemic absorption. Users discuss combining this method with oral treatments and minoxidil, noting potential benefits and side effects.

A 38-year-old considering switching from finasteride and minoxidil to dutasteride for hair maintenance, noting past success with finasteride but recent hair shedding. Users shared experiences, with some recommending dutasteride for better regrowth, while others noted potential shedding during the transition.

Dutasteride is used for hair regrowth, with some users experiencing side effects like reduced libido, changes in semen consistency, and emotional effects. Some users report positive hair regrowth results, while others experience issues like gynecomastia and fat accumulation.

A user switched from finasteride to dutasteride, taking dutasteride twice weekly and considering continuing finasteride on other days. Some users shared their experiences with similar switches, noting that dutasteride lowers DHT more effectively and advising against taking both simultaneously.

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

Microneedling, ketoconazole, and tretinoin are discussed as hair loss treatments, with tretinoin favored for its long-term benefits and potential to turn minoxidil non-responders into responders. Microneedling is recommended for initial use, ketoconazole for dandruff, and tretinoin for continuous use due to its skin benefits.

The conversation is about a person using dutasteride and minoxidil for hair loss, considering adding RU58841 and PP405 for more density. They are seeking advice on using these treatments and exploring other options like GT20029.

Switching from finasteride to dutasteride may lead to hair loss for some, with some users considering switching back to finasteride. Minoxidil, both oral and topical, is also used but results vary.

Hair loss treatments, specifically, discussing the effectiveness and side effects of finasteride, minoxidil, and RU58841 in various microdoses. It also includes an updated graph which provides information on how different doses affect DHT levels, scalp skin and serum androgen levels, as well as hair count.

Promising hair loss treatments in 2026 include GT20029, a topical androgen receptor degrader, and VDPHL01, an extended-release oral minoxidil, both offering safer alternatives with fewer side effects. Other treatments like sublingual minoxidil, OND-1, JW0061, TDM-105795, and AMP-303 are also being explored.

Clascoterone won't be available in the US until 2028, with EU filings planned for 2027. It's considered an alternative for those who experience side effects from standard treatments like finasteride and dutasteride.